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Abstract
In genetic association analysis, a joint test of multiple distinct phenotypes can
increase power to identify sets of trait‐associated variants within genes or
regions of interest. Existing multiphenotype tests for rare variants make specific
assumptions about the patterns of association with underlying causal variants,
and the violation of these assumptions can reduce power to detect association.
Here, we develop a general framework for testing pleiotropic effects of rare
variants on multiple continuous phenotypes using multivariate kernel regres-
sion (Multi‐SKAT). Multi‐SKAT models affect sizes of variants on the
phenotypes through a kernel matrix and perform a variance component test
of association. We show that many existing tests are equivalent to specific
choices of kernel matrices with the Multi‐SKAT framework. To increase power
of detecting association across tests with different kernel matrices, we
developed a fast and accurate approximation of the significance of the
minimum observed P value across tests. To account for related individuals,
our framework uses random effects for the kinship matrix. Using simulated data
and amino acid and exome‐array data from the METabolic Syndrome In Men
(METSIM) study, we show that Multi‐SKAT can improve power over single‐
phenotype SKAT‐O test and existing multiple‐phenotype tests, while maintain-
ing Type I error rate.
KEYWORD S
Copula, gene‐based test, METSIM study, multiple phenotypes, phenotype kernel, pleiotropy, rare
variants, related individuals, SKAT
1 | INTRODUCTION
Since the advent of array genotyping technologies,
genome‐wide association studies (GWASs) have identi-
fied numerous genetic variants associated with complex
traits. Despite these many discoveries, GWAS loci explain
only a modest proportion of heritability for most traits.
This may be due, in part, to the fact that these association
studies are underpowered to identify associations with
rare variants (Korte & Farlow, 2013). To identify such
rare‐variant associations, gene‐ or region‐based multiple
variant tests have been developed (Lee, Abecasis,
Boehnke, & Lin, 2014). By jointly testing rare variants
in a target gene or region, these methods can increase
power over a single‐variant test and are now used as a
standard approach in rare‐variant analysis.
Recent GWAS results have shown that many GWAS
loci are associated with multiple traits (Solovieff,
Cotsapas, Lee, Purcell, & Smoller, 2013). Nearly, 17% of
variants in National Heart Lung and Blood Institute
(NHLBI) GWAS categories is associated with multiple
traits (Sivakumaran et al., 2011). For example, 44% of
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autoimmune risk single‐nucleotide polymorphisms
(SNPs) has been estimated to be associated with two or
more autoimmune diseases (Cotsapas et al., 2011).
Detecting such pleiotropic effects is important to under-
stand the underlying biological structure of complex
traits. In addition, by leveraging cross‐phenotype associa-
tions, the power to detect trait‐associated variants can be
increased.
Identifying the cross‐phenotype effects requires a
suitable joint or multivariate analysis framework that
can leverage the dependence of the phenotypes. Various
methods have been proposed for multiple‐phenotype
analyses in GWAS (Ferreira & Purcell, 2009; Huang,
Johnson, & O’Donnell, 2011; Ray, Pankow, & Basu, 2016;
Ried et al., 2012; Zhou & Stephens, 2014). Extending
them, several groups have developed multiple‐phenotype
tests for rare variants (Broadaway et al., 2016; Lee et al.,
2016; Maity, Sullivan, & Tzeng, 2012; Sun et al., 2016;
Wang et al., 2015; Wu & Pankow, 2016; Yan et al., 2015;
Zhan et al., 2017). For example, Wang et al. (2015)
proposed a multivariate functional linear model (MFLM);
Broadaway et al. (2016) used a dual‐kernel‐based
distance‐covariance approach to test for cross‐phenotype
effects of rare variants by comparing similarity in
multivariate phenotypes to similarity in genetic variants
(GAMuT; Chiu et al., 2017); Wu and Pankow (2016)
developed a score‐based sequence kernel association test
for multiple traits, MSKAT, which has been shown to be
similar in performance to GAMuT (Broadaway et al.,
2016); Zhan et al. (2017) proposed a dual kernel based
association test (DKAT), which uses the dual‐kernel
approach as in GAMuT but provides more robust
performance when the dimension of phenotypes is high
compared with the sample size.
Despite these developments, existing methods have
important limitations. Most methods were developed
under specific assumptions regarding the effects of the
variants on multiple phenotypes, and hence lose power if
the assumptions are violated (Ray et al., 2016). For
example, if genetic effects are heterogeneous across
multiple phenotypes, methods assuming homogeneous
genetic effects can lose a substantial amount of power.
Although there has been a recent attempt to combine
analysis results from different models (Zhan et al., 2017),
no scalable methods have been developed to evaluate the
significance of the combined results in genome‐wide
scale analysis. In addition, most existing methods and
software cannot adjust for relatedness between indivi-
duals; thus, to apply these methods, related individuals
must be removed from the analysis to maintain Type I
error rate. For example, in the METabolic Syndrome In
Men (METSIM) study, ~15% of individuals is estimated to
be related up to the second degree.
Here, we develop Multi‐SKAT, a general framework
that extends the mixed effect model‐based kernel
association tests to a multivariate regression framework
while accounting for family relatedness. Mixed effect
models have been widely used for rare‐variant associa-
tion tests. Popular rare‐variant tests, such as SKAT (Wu
et al., 2011) and SKAT‐O (Lee, Wu, & Lin, 2012), are
based on mixed effect models. By using kernels to relate
genetic variants to multiple continuous phenotypes,
Multi‐SKAT allows for flexible modeling of the genetic
effects on the phenotypes. The idea of using kernels for
genotypes and phenotypes was previously used by the
dual‐kernel approaches, such as GAMuT and DKAT.
However, in contrast to these two similarity‐based
methods, Multi‐SKAT is multivariate regression based
and hence provides a natural way to adjust for covariates
and also can account for sample relatedness by incorpor-
ating random effects for the kinship matrix. Many of the
existing methods for multiple‐phenotype rare‐variant
tests can be viewed as special cases of Multi‐SKAT with
particular choices of kernels. Furthermore, to avoid loss
of power due to model misspecification, we develop
computationally efficient omnibus tests, which allow for
aggregation of tests over several kernels and provide fast
P value calculation (Demarta & McNeil, 2005).
The article is organized as follows: In the first section,
we present the multivariate mixed effect model and
kernel matrices. We particularly focus on the phenotype
kernel and describe omnibus procedures that can
aggregate results across different choices of kernels and
kinship adjustment. In the next section, we describe the
simulation experiments that clearly demonstrate that
Multi‐SKAT tests have increased power to detect
associations compared with existing methods, like
GAMuT, MSKAT, and others in most of the scenarios.
Further, we applied Multi‐SKAT to detect the cross‐
phenotype effects of rare nonsynonymous and protein‐
truncating variants on a set of nine amino acids
measured on 8,545 Finnish men from the METSIM study.
2 | MATERIALS AND METHODS
2.1 | Single‐phenotype region‐based
tests
To describe the Multi‐SKAT tests, we first present the
existing model of the single‐phenotype gene or region‐
based tests. Let y y y y= ( , ,…, )k k k nk T1 2 be an n × 1 vector
of the kth phenotype over n individuals; X an n q×
matrix of the q nongenetic covariates, including the
intercept; G G G= ( ,…, )j j nj T1 is an n × 1 vector of the
minor allele counts (0, 1, or 2) for a binary genetic variant
j; and G G G= [ ,…, ]m1 is an n m× genotype matrix for m
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genetic variants in a target region. The regression model
shown in Equation (1) can relate m genetic variants to
phenotype k:
y Xα Gβ= + + ϵ ,k k k k. (1)
where αk is a q × 1 vector of regression coefficients of q
nongenetic covariates, β β β= ( ,…, )k k mk T. 1 an m × 1 vector
of regression coefficients of the m genetic variants, and ϵk
an n × 1 vector of nonsystematic error term with each
element following N σ(0, )k2 . To test for βH : = 0k0 . , a
variance component test under the mixed effect model has
been proposed to increase power over the usual F test (Wu
et al., 2011). The variance component test assumes that the
regression coefficients, βk. , are random variables and follow
a centered distribution with variance τ ΣG2 (see below).
Under these assumptions, the test for β = 0k. is equivalent
to testing τ = 0. The score statistic for this test is
Q y μ GΣ G y μ= ( − ˆ ) ( − ˆ ),k k T G T k k (2)
where μ Xαˆ = ˆk k is the estimated mean of yk under the
null hypothesis of no association. The test statistic Q
asymptotically follows a mixture of Χ2 distributions
under the null hypothesis and P values can be computed
by inverting the characteristic function (Davies, 1980).
The kernel matrix ΣG plays a critical role; it models the
relationship among the effect sizes of the variants on the
phenotypes. Any positive semidefinite matrix can be used
for ΣG providing a unified framework for the region‐based
tests. A frequent choice of ΣG is a sandwich‐type matrix
WR WΣ =G G , where W w w= diag( , …, )m1 is a diagonal
weighting matrix for each variant, and RG is a correlation
matrix between the effect sizes of the variants. R I=G m m×
implies uncorrelated effect sizes and corresponds to SKAT,
and R = 1 1G m mT corresponds to the Burden test, where
Im m× is anm m× diagonal matrix and 1 = (1, …, 1)m T is an
m × 1 vector with all elements being unity. Furthermore, a
linear combination of these two matrices corresponds to
R ρ ρ I= 1 1 + (1 − )G m mT m m× , which is used for SKAT‐O
(Lee, Wu et al., 2012).
2.2 | Multiple‐phenotype region‐based
tests
Extending the idea of using kernels, we build a model for
multiple phenotypes. The multivariate linear model
shown in Equation (3) can relate genetic variants to
K ‐correlated phenotypes:
Y XA GB E= + + , (3)
where Y y y= ( , …, )K1 is an n K× phenotype matrix, A a
q K× matrix of coefficients of X , B = β( )ij an m K×
matrix of coefficients, where βij denotes the effect of the
ith variant on the jth phenotype, and E an n K× matrix
of nonsystematic errors. Let ⋅vec( ) denote the matrix
vectorization function, and then Evec( ) follows
⊗N I V(0, )n , where V is a K K× covariance matrix
and ⊗ represents the Kronecker product.
In addition to assuming that βk. follows a centered
distribution with covariance τ ΣG2 , we further assume that
β β β= ( , …, )i i iK T. 1 , which is the vector of regression coeffi-
cients of variant i for K multiple phenotypes, follows a
centered distribution with covariance τ ΣP2 , which implies
that Bvec( ) follows a centered distribution with covariance
⊗τ Σ ΣG P2 . As before, the null hypothesis BH : vec( ) = 00 is
equivalent to τ = 0. The corresponding score test statistic is

 ⊗
Q Y μ GΣ G
V Σ V Y μ
= {vec( ) − vec( )} {( )
( )}{vec( ) − vec( )},
T
G
T
P
−1 −1 (4)
where μ and V are the estimated mean and covariance of
Y under the null hypothesis.
ΣP plays a similar role as ΣG but with respect to
phenotypes. ΣP represents a kernel in the phenotypes
space and models the relationship among the effect sizes
of a variant on each of the phenotypes. Any positive
semidefinite matrix can be used as ΣP.
The proposed approach provides a double flexibility in
modeling. Through the choice of structures for ΣG and ΣP,
we can control the dependencies of genetic effects.
Additionally, similar to SKAT, the use of a sandwich‐
type matrix WR WG for ΣG allows us to upweight rare
variants by using β (1, 25) weights as in Wu et al. (2011).
Most of our hypotheses about the underlying genetic
structure of a set of phenotypes can be modeled through
varying structures of these two matrices.
2.3 | Phenotype kernel structure ΣP
The use of ΣG has been extensively studied previously in
the literature (Lee, Emond et al., 2012; Lee, Wu, et al.,
2012; Wu et al., 2011). Here, we propose several choices
for ΣP and study their effect from a modeling perspective.
2.3.1 | Homogeneous (Hom) kernel
It is possible that effect sizes of a variant on different
phenotypes are homogeneous, in which case ⋯β β= =j jK1 .
Under this assumption,
Σ = 1 1 .P K KT,Hom (5)
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Under ΣP,Hom, the effect sizes β k K, ( = 1, …, )jk for a
variant j are the same for all the phenotypes.
2.3.2 | Heterogeneous (Het) kernel
Effect sizes of a variant on different phenotypes can be
heterogeneous, in which ≠⋯≠β βj jK1 . Under this as-
sumption, we can construct
IΣ = .P k k,Het × (6)
The ΣP,Het implies that the effect sizes (β β, …,j jK
T
1 ) are
uncorrelated among themselves. This also indicates that
the correlation among the phenotypes is not affected by
this particular region or gene.
2.3.3 | Phenotype covariance (PhC)
kernel
We may model ΣP as proportional to the estimated
residual covariance across the phenotypes as
VΣ = ,P,PhC (7)
where V is the estimated covariance matrix among the
phenotypes. This model assumes that the correlation
between the effect sizes is proportional to that between
the residual phenotypes after adjusting for the nongenetic
covariates.
2.3.4 | Principal component (PC) kernel
Principal component analysis (PCA) is a popular tool for
multivariate analysis. In multiple‐phenotype tests,
PC‐based approaches have been used to reduce the
dimension in phenotypes (Aschard et al., 2014). Here, we
show that PC‐based approach can be included in our
framework. Let L L L= ( , …, )K1 be the loading matrix with
each column Li produces the ith PC score. In Appendix
A, we show that using    VLV V L VΣ =P P P T,PC −1 −1 is
equivalent to assuming heterogeneous effects with all
PCs as phenotypes. Instead of using all the PCs, we can
use selected PCs that represent the majority of cumula-
tive variations in phenotypes. For example, we can jointly
test the PCs that have cumulative variance of 90%. If the
top t PCs have been chosen for analysis using ν%
cumulative variance as cutoff, we can use
   VL V V L VΣ = ,P ν P P T,PC− sel −1 −1 sel
where L L L= [ , …, , 0, …, 0]tsel 1 and 0 represents a vector
of 0’s of appropriate length.
2.3.5 | Relationship with other
multiple‐phenotype rare‐variant tests
We have proposed a uniform framework of Multi‐SKAT
tests that depend on ΣG and ΣP. There are certain specific
choices of kernels that correspond to other published
methods.
• Using ΣP,PhC and WI WΣ =G m T is identical to the
GAMuT (Broadaway et al., 2016) with the projection
phenotype kernel and the MSKAT with the Q statistic
(Wu & Pankow, 2016).
• Using VΣ =P 2 and WI WΣ =G m T is identical to
GAMuT (Broadaway et al., 2016) with the linear
phenotype kernel and the MSKAT with the Q′ statistic
(Wu & Pankow, 2016).
• Using ΣP,Hom and WI WΣ =G m T is identical to hom‐
MAAUSS (Lee et al., 2016).
• Using ΣP,Het and WI WΣ =G m T is identical to het‐
MAAUSS (Lee et al., 2016) and MF‐KM (Yan et al., 2015).
For the detailed proof, please see Appendix B.
2.4 | Minimum P value‐based omnibus
tests (minP and minPcom)
The model and the corresponding test of association that
we propose have two parameters, ΣG and ΣP, which are
absent in the null model of no association. Because our
test is a score test, ΣG and ΣP cannot be estimated from
the data. One possible approach is to select ΣG and ΣP
based on prior knowledge; however, if the selected ΣG
and ΣP do not reflect underlying biology, the test may
have substantially reduced power (Lee et al., 2016; Ray
et al., 2016). In an attempt to achieve robust power, we
aggregate results across different ΣG and ΣP using the
minimum of P values from different kernels.
Although this omnibus test approach has been used in
rare‐variant tests and multiple‐phenotype analyses for
combining multiple kernels from genotypes and pheno-
types (He, Xu, Lee, & Ionita‐Laza, 2017; Urrutia et al.,
2015; Wu, Maity, Lee, & Simmons, 2013; Zhan et al.,
2017), it is challenging to calculate the P value, because
the minimum P value does not follow the uniform
distribution. One possible approach is using permutation
or perturbation to calculate the Monte‐Carlo P value
(Urrutia et al., 2015; Zhan et al., 2017); however, this
approach is computationally too expensive to be used in
genome‐wide analysis. To address it, here we propose a
fast Copula‐based P value calculation for Multi‐SKAT,
which needs only a small number of resampling steps to
calculate the P value.
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Suppose ph is the P value forQh with given hth ΣG and
ΣP, h b= 1,…, , and T p p= ( , …, )P b T1 is a b × 1 vector of
P values of b such Multi‐SKAT tests. The minimum
P value test statistic after the Bonferroni adjustment is
b × pmin, where pmin is the minimum of the b P values. In
the presence of positive correlation among the tests, this
approach is conservative and hence might lack power of
detection. Rather than using the Bonferroni‐corrected
pmin, more accurate results can be obtained if the joint
null distribution or more specifically the correlation
structure of TP can be estimated. Here, we adopt a
resampling‐based approach to estimate this correlation
structure. Note that our test statistic is equivalent to
 ⎜ ⎟⎧⎨⎩
⎛
⎝
⎞
⎠
⎫⎬⎭⊗Q S G G V V S= ( Σ ) Σ ,
T
G
T
P
− 12 −
1
2 (8)
where ⊗S I V Y μ= ( ){vec( ) − vec( )}n −
1
2 . Under the null
hypothesis, S approximately follows an uncorrelated
normal distribution N I(0, )nK . Using this, we propose
the following resampling algorithm:
1. Generate nK samples from an N (0, 1) distribution,
say SR.
2. Calculate b different test statistics as Q S=R RT
 ⊗G G V V S{( Σ ) ( Σ )}G T P R− −
1
2
1
2 for all the choices of ΣP
and calculate P values.
3. Repeat the previous steps independently for
R (=1,000) iterations and calculate the correlation
between the P values of the tests from the R
resampling P values.
With the estimated null‐correlation structure, we use
a Copula to approximate the joint distribution of TP
(Demarta & McNeil, 2005; He et al., 2017). Copula is a
statistical approach to construct joint multivariate
distribution using marginal distribution of each variable
and correlation structure. Because marginally each test
statistic Q follows a mixture of Χ2 distributions, which
has a heavier tail than normal distribution, we propose to
use a t‐Copula to approximate the joint distribution, that
is, we assume the joint distribution of TP to be multi-
variate t with the estimated correlation structure. The
final P value for association is then calculated from the
distribution function of the assumed t‐Copula.
When calculating the correlation across the P values,
Pearson’s correlation coefficient can be unreliable be-
cause it depends on normality and homoscedasticity
assumptions. To avoid such assumptions, we recommend
estimating the null‐correlation matrix of the P values
through Kendall’s tau τ( ), which is a nonparametric
approach based on concordance of ranks.
The minimum P value approach can be used to
combine different ΣP’s given ΣG, or combine both ΣP and
ΣG. For example, two ΣG’s corresponding to SKAT (WW )
and Burden kernels (W W1 1m mT ) and four ΣP’s (ΣP,Hom,
ΣP,Het, ΣP,PhC, and ΣP,PC−0.9) can be combined, which
results in the omnibus test of these eight different tests.
To differentiate the latter, we will call it minPcom, which
combines SKAT and Burden‐type kernels of ΣG.
2.5 | Adjusting for relatedness
We formulated Equation (3) and corresponding tests
under the assumption of independent individuals. If
individuals are related, this assumption is no longer valid,
and the tests may have inflated Type I error rate. Because
our method is regression based, we can relax the
independence assumption by introducing a random effect
term to account for the relatedness among individuals.
LetΦ be the kinship matrix of the individuals andVg is
a coheritability matrix, denoting the shared heritability
between the phenotypes. Extending the model presented
in Equation (3), we incorporate Φ and Vg as
Y XA GB Z E= + + + , (9)
where Z is an n K× matrix with Zvec( ) following
⊗N Φ V(0, )g . Z represents a matrix of random effects
arising from shared genetic effects between individuals
due to the relatedness. The remaining terms are the same
as in Equation (3). The corresponding score test
statistic is
 ⊗∕ ∕Q S V G G V S= {( Σ ) Σ } ,K KT G T P Kin in e−1 2 e−1 2 in (10)
where  ∕S V Y μ= {vec( ) − vec( )}K in e−1 2 and  ⊗V Φ=e ⊗V I V+g n is the estimated covariance matrix of Yvec( )
under the null hypothesis. Similar to the previous versions
for unrelated individuals, QK in asymptotically follows a
mixture of Χ2 under the assumption of no association.
This approach depends on the estimation of the matrices
Φ, Vg, and V . The kinship matrix Φ can be estimated
using the genome‐wide genotype data (Manichaikul et al.,
2010). Several of the published methods, like LD‐Score
(Bulik‐Sullivan et al., 2015), phenotype imputation expedited
(PHENIX) (Dahl et al., 2016), and genome-wide efficient
mixed model association (GEMMA) (Zhou & Stephens,
2014; Zhou, Carbonetto, & Matthew, 2013) can jointly
estimate Vg and V . In our numerical analysis, we have used
PHENIX. This is an efficient method to fit local maximum
likelihood variance components in a multiple‐phenotype‐
mixed model through an E–M algorithm.
Once the matrices Φ, Vg, and V are estimated, we
compute the asymptotic P values for QK in by using a
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mixture of Χ2 distribution. The computation of QK in
requires large matrix multiplications, which can be time
and memory consuming. To reduce computational
Burden, we employ several transformations. We perform
an eigen decomposition on the kinship matrix Φ as
Φ UΛU= T , where U is an orthogonal matrix of
eigenvectors and Λ is a diagonal matrix of corresponding
eigenvalues. We obtain the transformed phenotype
matrix as
∼Y U′Y= , the transformed covariate matrix as
∼X U′X= , the transformed random effects matrix
∼Z U′Z= and transformed residual error matrix
∼E U′E= . Equation (9) can be transformed into
⊗
⊗
∼ ∼ ∼ ∼
∼
∼ ∼Y X A GB Z E Z N Λ V
E N I V
= + + + , vec( ) ~ (0, ),
vec( ) ~ (0, ).
g
(11)
All the properties of the tests developed from Equation (3)
are directly applicable to those from Equation (11).QK in can
be computed from this transformed equation as
⊗͠ ͠
∼ ∼∼ ∼∕ ∕Q S V G G V S= {( Σ ) Σ } ,K K
T
G
T
P Kin in e
−1 2
e
−1 2
in (12)
where ∼͠
∼∼ ∕S V Y μ= {vec( ) − vec( )}K in e
−1 2
, ∼μ is the estimated
mean of
∼Y under the null hypothesis and
 ⊗ ⊗∼V Λ V I V= +g ne . Asymptotic P values can be
obtained from the corresponding mixture of Χ2 distribu-
tion. Further, omnibus strategies for the tests developed
from Equation (3) are applicable in this case with similar
modifications. For example, the resampling algorithm for
minimum P value‐based omnibus test can be implemen-
ted here as well by noting that S͠K in approximately follows
an uncorrelated normal distribution.
3 | SIMULATIONS
We carried out extensive simulation studies to evaluate the
Type I error control and power of Multi‐SKAT tests. For
Type I error simulations without related individuals and all
power simulations, we generated 10,000 chromosomes over
1Mbp regions using a coalescent simulator with the
European demographic model (Schaffner et al., 2005). The
minor allele frequency (MAF) spectrum of the simulated
variants is shown in Supporting Information Figure S6,
showing that most of the variants are rare variants. Because
the average length of the gene is 3 kbps, we randomly
selected a 3‐kbps region for each simulated data set to test
for associations. For the Type I error simulations with
related individuals, to have a realistic kinship structure, we
used the METSIM study genotype data.
Phenotypes were generated from the multivariate
normal distribution as
⋯y β G β G I V~ MVN{( + + ) , },i m m1 1 (13)
where y y y= ( ,…, )i i iK T1 is the outcome vector, Gj the
genotype of the jth variant, and βj the corresponding
effect size, and V a covariance of the nonsystematic error
term. We use V to define level of covariance between the
traits. I is a k × 1 indicator vector, which has 1 when the
corresponding phenotype is associated with the region
and 0 otherwise. For example, if there are five
phenotypes and the last three are associated with the
region, I = (0, 0, 1, 1, 1)T .
To evaluate whether Multi‐SKAT can control Type I error
under realistic scenarios, we simulated a data set with nine
phenotypes with a correlation structure identical to that of
nine amino acid phenotypes in the METSIM data (see
Supporting Information Figure S1). Phenotypes were gener-
ated using Equation (13) with β = 0. Total 5,000,000 data
sets with 5,000 individuals were generated to obtain the
empirical Type I error rates at α = 10 , 10−4 −5, and
2.5 × 10−6, which are corresponding to candidate gene
studies to test for 500 and 5,000 genes and exome‐wide
studies to test for all 20,000 protein coding genes,
respectively.
Next, we evaluated Type I error controls in the presence
of related individuals. To have a realistic related structure, we
used the METSIM study genotype data. We generated a
random subsample of 5,000 individuals from the
METSIM study individuals and generated null values for
the nine phenotypes from VMVN(0, ),e where ⊗ ⊗V Φ V I V= +ge 5k ;5k 5k, Φ5k is the estimated kinship
matrix of the 5,000 selected individuals, Vg;5k and V5k are
estimated coheritability and residual variance matrices,
respectively, for these individuals as estimated using the
multiple phenotype mixed model (MPMM) function in the
PHENIX R‐package (version 1.0 See Web Resources). For
each set of nine phenotypes, we performed the Multi‐SKAT
tests for randomly selected 5,000 genes in the METSIM data.
For the details about the data, see the next section. We
carried out this procedure 1,000 times and obtained
5, 000, 000 P values and estimated Type I error rate as
proportions of P values smaller than the given level α.
Our simulation studies focus on evaluating the power of
the proposed tests when the number of phenotypes is five or
six. Power simulations were performed both in situations
when there was no pleiotropy (i.e., only one of the
phenotypes was associated with the causal variants) and
also when there was pleiotropy. Under pleiotropy, because it
is unlikely that all the phenotypes are associated with
genotypes in the region, we varied the number of phenotypes
associated. For each associated phenotype, 30% or 50% of the
rare variants (MAF< 1%) was randomly selected to be
causal variants. We modeled the rarer variants to have
stronger effect, as ∣ ∣ ∣ ∣β c= log (MAF )j j10 . We used c = 0.3,
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which yields ∣ ∣β = 0.9j for variants with MAF= 10−3. Our
choice of β yielded the average heritability of associated
phenotypes between 1% and 4%. We also considered
situations that all causal variants were trait‐increasing
variants (i.e., positive β) or 20% of causal variants was
trait‐decreasing variants (i.e., negative β). Empirical power
was estimated from 1,000 independent data sets at exome‐
wide α = 2.5 × 10−6.
In Type I error and power simulations, we compared
the following tests:
• Bonferroni‐adjusted minimum P values from gene‐
based test (SKAT, Burden, or SKAT‐O) on each
phenotype (minPhen),
• Multi‐SKAT with ΣP,Hom (Hom),
• Multi‐SKAT with ΣP,Het (Het),
• Multi‐SKAT with ΣP,PhC (PhC),
• Multi‐SKAT with ΣP,PC−0.9 (PC‐Sel),
• Minimum P value of Hom, Het, PhC, and PC‐Sel using
Copula (minP),
• Minimum P value of Hom, Het, PhC, and PC‐Sel with
ΣG being SKAT and Burden, using Copula (minPcom).
For the Multi‐SKAT tests, we used two different ΣG’s
corresponding to SKAT (i.e., WWΣ =G ) and Burden tests
(i.e., W WΣ = 1 1G m mT ). For the variant weighting matrix
W w w= diag( ,…, )m1 , we used w β= (MAF , 1, 25)j j func-
tion to upweight rarer variants, as recommended by Wu
et al. (2011).
3.1 | Computation time
We estimated the computation time of Multi‐SKAT tests and
the existing methods. Using simulated data sets of 5,000
related and unrelated individuals with 10 phenotypes and 20
genetic variants, we estimated the computation time of
Multi‐SKAT tests with and without kinship adjustments. To
compare the computation performance of Multi‐SKAT tests
with the existing methods, we generated data sets of
unrelated individuals with five different sample sizes
(n=1,000, 2,000, 10,000, 15,000, and 20,000) and four
different number of variants (m = 10, 20, 50, and 100).
For each simulation setup, we generated 100 data sets and
obtained the average value of the computation time.
3.2 | Analysis of the METSIM study
ExomeChip data
To investigate the cross‐phenotype roles of low frequency
and rare variants on amino acids, we analyzed data on
8,545 participants of the METSIM study on whom all
nine amino acids (alanine, leucine, isoleucine, glycine,
valine, tyrosine, phenylalanine, glutamine, and histidine)
were measured by proton nuclear magnetic resonance
spectroscopy (Teslovich et al., 2018). Individuals were
genotyped on the Illumina ExomeChip and OmniExpress
arrays, and we included individuals that passed sample
quality control filters (Huyghe et al., 2013). The kinship
between the individuals was estimated via KING (version
2.0; Manichaikul et al., 2010, See Web Resources). We
adjusted the amino acid levels for age, age2, and BMI and
inverse normalized the residuals. The phenotype correla-
tion matrix after covariate adjustment is shown in Figure
3 and Supporting Information Figure S1. Subsequently,
we estimated the genetic heritability matrix and the
residual covariance matrix using the MPMM function
from PHENIX R‐package (Dahl et al., 2016).
We included rare (MAF< 1%) nonsynonymous and
protein‐truncating variants with a total rare minor allele
count of at least five for genes that had at least three rare
variants leaving 5,207 genes for analysis. We set a
stringent significance threshold at 9.6 × 10−6 correspond-
ing to the Bonferroni adjustment for 5,207 genes. Further,
we also considered a less stringent threshold of 10−4,
corresponding to a candidate gene study of 500 genes, as
suggestive to study the associations, which were not
significant but close to the threshold.
4 | RESULTS
4.1 | Type I error simulations
We estimated empirical Type I error rates of the Multi‐
SKAT tests with and without related individuals. For
unrelated individuals, we simulated 5,000 individuals
and nine phenotypes based on the correlation structure
for the amino acid phenotypes in the METSIM study
data. For related individuals, we simulated 5,000
individuals using the kinship matrix for randomly
chosen METSIM individuals (see Section 2). We
performed association tests and estimated Type I error
rate as the proportion of P values less than the specified
α levels. Type I error rates of the Multi‐SKAT tests were
well maintained at α = 10 , 10−4 −5, and 2.5 × 10−6 for
both unrelated and related individuals (Table 1), which
correspond to candidate gene studies of 500 and
5,000 genes and exome‐wide studies to test for all
20,000 protein coding genes, respectively. For example,
at level α = 2.5 × 10−6, the largest empirical Type I
error rate from any of the Multi‐SKAT tests was
3.4 × 10−6, which was within the 95% confidence
interval (CI = [1.6 × 10−6, 4 × 10−6]).
4.2 | Power simulations
We compared the empirical power of the minPhen
(Bonferroni‐adjusted minimum P value for the
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phenotypes) and Multi‐SKAT tests. For each simulation
setting, we generated 1,000 sequence data sets of 5, 000
unrelated individuals and for each test estimated
empirical power as the proportion of P values less than
α = 2.5 × 10−6, reflecting the Bonferroni correction for
testing 20,000 independent genes. Because the Hom and
Het tests are identical to hom‐MAAUSS and het‐
MAAUSS, respectively, and using PhC is identical to
both GAMuT (with projection phenotype kernel) and
MSKAT, our power simulation studies effectively com-
pare the existing multiple‐phenotype tests.
In Figure 1, we show the results for five phenotypes
with compound symmetric correlation structure with
the correlation 0.3 or 0.7, where 30% of rare variants
(MAF< 0.01) was positively associated with 1, 2, or 3
phenotypes. Because it is unlikely that all the pheno-
types are associated with the region, we restricted the
number of associated phenotypes to at most 3. In most
scenarios, PhC, PC‐Sel, and Het had greater power
among the Multi‐SKAT tests with fixed phenotype
kernels (i.e., Hom, Het, PhC, and PC‐Sel), whereas
minP maintained high power as well. For example,
when the correlation between the phenotypes was 0.3
(i.e., ρ = 0.3) and the SKAT kernel was used for the
genotype kernel ΣG, if three phenotypes were asso-
ciated with the region, minP and PhC were more
powerful than that of the other tests. If the correlation
between the phenotypes was ρ = 0.7 and the Burden
kernel was used for genotype kernel ΣG, Het, PC‐Sel,
and minP had higher power than the rest of the tests
when two phenotypes were associated. It is noteworthy
that Hom had the lowest power in all the scenarios of
Figure 1.
Figure 2 demonstrates scenarios involving six pheno-
types and clustered correlation structures where PhC was
outperformed by other choices of the phenotype kernel
ΣP. When all three phenotype clusters had associated
phenotypes and the correlation within the clusters was
low (ρ = 0.3; Figure 2, upper panel), Hom and minP tests
outperformed PhC when the SKAT kernel was used. This
may be because that the phenotype correlation structure
did not reflect the genetic association pattern. When two
small clusters had high within‐cluster correlation
(ρ = 0.7) and one large cluster had low within‐cluster
TABLE 1 Empirical Type I error rates of the Multi‐SKAT tests from 5,000,000 simulated null data sets
Level ΣG minPhen Hom Het PhC PC‐Sel minP minPcom
Independent samples (without kinship adjustment)
SKAT 2.4 × 10−06 2.6 × 10−06 2.6 × 10−06 2.8 × 10−06 2.6 × 10−06 3.4 × 10−06
2.5 × 10−06 2.8 × 10−06
Burden 2.4 × 10−06 2.8 × 10−06 2.6 × 10−06 2.6 × 10−06 2.6 × 10−06 3.0 × 10−06
SKAT 9.6 × 10−06 9.6 × 10−06 9.8 × 10−06 9.8 × 10−06 9.8 × 10−06 9.4 × 10−06
10−05 1.2 × 10−05
Burden 9.4 × 10−06 9.6 × 10−06 9.8 × 10−06 9.6 × 10−06 9.6 × 10−06 9.6 × 10−06
SKAT 9.6 × 10−05 9.4 × 10−05 9.6 × 10−05 9.8 × 10−05 9.8 × 10−05 9.8 × 10−05
10−04 1.1 × 10−04
Burden 9.8 × 10−05 9.6 × 10−05 9.4 × 10−05 9.7 × 10−05 9.6 × 10−05 9.7 × 10−05
Related samples (with kinship adjustment)
SKAT 2.2 × 10−06 2.4 × 10−06 2.4 × 10−06 2.8 × 10−06 2.6 × 10−06 3.0 × 10−06
2.5 × 10−06 2.6 × 10−06
Burden 2.2 × 10−06 2.6 × 10−06 2.4 × 10−06 2.6 × 10−06 2.4 × 10−06 3.2 × 10−06
SKAT 9.6 × 10−06 9.8 × 10−06 9.8 × 10−06 9.8 × 10−06 9.8 × 10−06 9.4 × 10−06
10−05 1.4 × 10−05
Burden 9.7 × 10−06 9.6 × 10−06 9.4 × 10−06 9.4 × 10−06 9.4 × 10−06 9.4 × 10−06
SKAT 9.4 × 10−05 9.6 × 10−05 9.7 × 10−05 9.8 × 10−05 9.4 × 10−05 9.8 × 10−05
10−04 1.2 × 10−04
Burden 9.5 × 10−05 9.7 × 10−05 9.6 × 10−05 9.8 × 10−05 9.8 × 10−05 9.7 × 10−05
Note. Het: heterogeneous; Hom: homogeneous; METSIM: METabolic Syndrome In Men; minP: minimum P value; PC: principal component; PhC: phenotype
covariance.
The number of phenotypes was nine, and the correlation structure among the phenotypes was similar to that of the amino acid phenotypes in the METSIM
study data. The sample size was 5,000.
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correlation (ρ = 0.3; Figure 2, lower panel), Het and
minP had higher power than PhC.
When 20% of causal variants was trait‐decreasing
variants (80% trait‐increasing), the power of Multi‐SKAT
tests with Burden ΣG was reduced (Supporting Informa-
tion Figures S2 and S3). This is because the association
signals were attenuated due to the mix of trait‐increasing
and trait‐decreasing variants. Because SKAT is robust
regardless of the association direction, power with SKAT
ΣG was largely maintained. The relative performance of
methods with different ΣP given ΣG was quantitatively
similar to the results without trait‐decreasing variants.
Further, we estimated power of minPcom, which
combines tests across phenotype (ΣP) and genotype ΣG
kernels. The power of minPcom was evaluated for the
compound symmetric phenotype correlation structure pre-
sented in Figure 1 and was compared with the two minP
tests of SKAT (minP‐SKAT) and Burden (minP‐Burden) ΣG
kernels. Figure 3 shows empirical power with and without
trait‐decreasing variants. When all genetic effect coefficients
were positive (Figure 3, left panel), the performances of
minP‐SKAT and minP‐Burden were similar for both the
situations where the correlations between the phenotypes
were low (i.e., ρ = 0.3) and high (i.e., ρ = 0.7). When
FIGURE 1 Power for Multi‐SKAT tests when phenotypes have compound symmetric correlation structures. Empirical power for
minPhen, Hom, Het, PhC, PC‐Sel, and minP plotted against the number of phenotypes associated with the gene of interest with a total of five
phenotypes under consideration. Upper row shows the results for ρ = 0.3 and lower row for ρ = 0.7. Left column shows the results with the
SKAT kernel ΣG, and right columns shows the results with the Burden kernel. All the causal variants were trait‐increasing variants. Het:
heterogeneous; Hom: homogeneous; minP: minimum P value; PC: principal component; PhC: phenotype covariance
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20% of genetic effect coefficients was negative (Figure 3, right
panel), as expected, the power of minP‐Burden was
substantially decreased. Across all the situations, the power
of minPcom was similar to the most powerful minP with
fixed genotype kernel ΣG. When 50% of variants was causal
variants and all genetic effect coefficients were positive
(Supporting Information Figure S4, left panel), minP‐Burden
was more powerful than minP‐SKAT, and minPcom had
similar power than minP‐Burden.
Overall, our simulation results show that the omnibus
tests, especially minPcom, had robust power throughout
all the simulation scenarios considered. When ΣG and ΣP
were fixed, power depended on the model of association
and the correlation structure of the phenotypes. Overall,
the proposed Multi‐SKAT tests generally outperformed
the single‐phenotype test (minPhen), even when only one
phenotype was associated with genetic variants.
4.3 | Application to the METSIM study
ExomeChip data
Inborn errors of amino acid metabolism cause mild to
severe symptoms, including type 2 diabetes (Stančáková
et al., 2012; Würtz et al., 2012, 2013) and liver diseases
(Tajiri & Shimizu, 2013) among others. Amino acid levels
are perturbed in certain disease states, for example,
glutamic and aspartic acid levels are reduced in
Alzheimer disease brains (Allan Butterfield & Pocernich,
FIGURE 2 Power for Multi‐SKAT tests when phenotypes have clustered correlation structures. Empirical powers for minPhen, Hom,
Het, PhC, PC‐Sel, and minP are plotted under different levels of association with a total of six phenotypes and with clustered correlation
structures. Middle column shows the empirical powers for different combinations of phenotypes associated with the SKAT kernel ΣG; the
rightmost column shows the corresponding results with the Burden kernel; left column shows the corresponding correlation matrices for the
phenotypes. The associated phenotypes are indicated in red cross marks across the correlation matrices. All the causal variants were
trait‐increasing variants. Het: heterogeneous; Hom: homogeneous; minP: minimum P value; PC: principal component; PhC: phenotype
covariance
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2003); isoleucine, glycine, alanine, phenylalanine, and
threonine levels are increased in cerebo‐spinal fluid
(CSF) of individuals with motor neuron disease (de
Belleroche & Recordati, 2003). To find rare variants
associated with the nine measured amino acid levels, we
applied the Multi‐SKAT tests to the METSIM study data
(Teslovich et al., 2018). The MAF spectrum of the
genotyped variants is shown in Supporting Information
Figure S6, showing that most of the variants are rare
variants. We estimated the relatedness between indivi-
duals by KING (Manichaikul et al., 2010) and coherit-
ability of the amino acid phenotypes and the
corresponding residual variance using PHENIX (Dahl
et al., 2016; Supporting Information Figure S1). Among
the 8,545 METSIM participants with nonmissing pheno-
types and covariates, 1,332 individuals had a second
degree or closer relationship with one or more of the
METSIM participants. A total of 5, 207 genes with at least
three rare variants were included in our analysis. The
Bonferroni corrected significance threshold was
∕α = 0.05 5207 = 9.6 × 10−6. Further, we used a less
significant cutoff of α = 10−4 for a gene to be suggestive.
After identifying associated genes, we carried out back-
ward elimination procedure (Appendix C) to investigate
which phenotypes are associated with the gene. This
procedure iteratively removes phenotypes based on
minPcom P values.
Quantile‐quantile (QQ) plots for the P values obtained
by minPhen and Multi‐SKAT omnibus tests (minP and
minPcom) are displayed in Figure 4. Due to the presence
FIGURE 3 Power for Multi‐SKAT by combining tests with ΣP as Hom, Het, PhC, PC‐Sel, and ΣG as SKAT and Burden when phenotypes have
compound symmetric correlation structures. Empirical powers for minP‐Burden, minP‐SKAT, and minPcom are plotted against the number of
phenotypes associated with the gene of interest with a total of five phenotypes under consideration. Upper row shows the results for ρ = 0.3 and
lower row for ρ = 0.7. Left column shows the results when all the causal variants were trait‐increasing variants, and right column shows the results
when 80%/20% of the causal variants was trait‐increasing/trait‐decreasing variants. Het: heterogeneous; Hom: homogeneous; minP: minimum
P value; PC: principal component; PhC: phenotype covariance
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of several strong associations, for the ease of viewing, any
P value < 10−12 was collapsed to 10−12. The QQ plots are
well calibrated with slight inflation in tail areas. The
genomic‐control lambda (λGC) varied between 0.97 and
1.04, which indicates no inflation of test statistics. Table 2
shows genes with P values less than 10−4 for minPhen or
minPcom. Table 5 shows SKAT‐O P values for each of the
gene–amino acid pairs. Among the eight significant or
suggestive genes displayed in Table 2, minPcom provides
more significant P values than minPhen for six genes:
Glycine decarboxylase (GLDC [MIM: 238300]), histidine
ammonia‐lyase (HAL [MIM: 609457]), phenylalanine
hydroxylase (PAH [MIM: 612349]), dihydroorotate
dehydrogenase (DHODH [MIM: 126064]), mediator of
RNA polymerase II transcription subunit 1 (MED1 [MIM:
604311]), and serine/threonine kinase 33 (STK33 [MIM:
607670]). Interestingly, PAH andMED1 are significant by
minPcom, but not significant by minPhen. PAH encodes
an phenylalanine hydroxylase, which catalyzes the
hydroxylation of the aromatic side‐chain of phenylalanine
FIGURE 4 QQ plot of the P values of minPhen and Multi‐SKAT omnibus tests for the METSIM data. For the ease of viewing, any
associations with P values < 10−12 have been collapsed to 10−12. METSIM: METabolic Syndrome In Men; QQ: quantile quantile
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to generate tyrosine. MED1 is involved in the regulated
transcription of nearly all RNA polymerase II‐dependent
genes. This gene does not show any single‐phenotype
association, but cross‐phenotype analysis produced
evidence of association. Using backward elimination, we
find that phenylalanine and tyrosine are the last two
phenotypes to be eliminated (Supporting Information
Table S2). We have provided a detailed description of
the function and clinical implications of the significant
and suggestive genes in Supporting Information Table S4.
TABLE 2 Significant and suggestive genes associated with nine amino acid phenotypes
Gene Chromosome Rare SNPs MAC minPhen minP‐SKAT minP‐Burden minPcom
GLDC 9 4 183 102.2 × 63− 101.1× 72− 109.7 × 64− 102.3 × 72−
HAL 3 6 42 102.9 × 08− 1.1 × 10−05 104.2 × 11− 109.5 × 11−
DHODH 16 5 90 101.3 × 06− 109.7 × 08− 107.7 × 06− 101.1 × 07−
PAH 12 6 27 6.1 × 10−04 101.4 × 06− 101.3 × 06− 101.9 × 06−
MED1 17 3 147 6.2 × 10−01 103.9 × 06− 3.4 × 10−04 104.9 × 06−
STK33 11 6 180 8.9 × 10−01 3.2 × 10−05 3.3 × 10−02 4.2 × 10−05
ALDH1L1 3 8 103 108.4 × 08− 3.8 × 10−04 4.2 × 10−05 5.4 × 10−05
BCAT2 19 3 133 1.1 × 10−05 9.3 × 10−03 3.4 × 10−05 6.2 × 10−05
Note. MAF: minor allele frequency; minP: minimum P value using copula; SNP: single‐nucleotide polymorphism; MAC: minor allele count.
Genes with P values < 10−4 by minPhen or any Multi‐SKAT tests (minP‐SKAT, minP‐Burden, and minPcom) were reported in this table. Multi‐SKAT tests were
applied with the kinship adjustment, and 5,207 genes with at least three rare (MAF< 0.01) nonsynonymous and protein‐truncating variants were used in this
analysis. The total sample size was n= 8,545. P values smaller than the Bonferroni corrected significance α = 9.6 × 10−6 were marked as bold. Smallest P values
for each gene among all the tests have been underlined. minPhen was calculated as the Bonferroni‐adjusted minimum SKAT‐O P value across each phenotype.
TABLE 3 P values for Multi‐SKAT tests (Hom, Het, PhC, PC‐Sel, and minP) with SKAT and Burden kernels for the genes reported in
Table 2
Gene Multi‐SKAT
ΣG Name Chromosome
Rare
SNPs MAC minPhen Hom Het PhC PC‐Sel minP
GLDC 9 4 183 106.8 × 63− 1.3 × 10−03 101.3 × 17− 102.9 × 73− 105.3 × 59− 101.1 × 72−
DHODH 16 5 90 105.1 × 08− 1.4 × 10−01 3.2 × 10−03 103.1 × 08− 107.1 × 06− 109.7 × 08−
PAH 12 6 27 4.3 × 10−05 7.9 × 10−02 1.8 × 10−05 103.9 × 07− 6.3 × 10−04 101.4 × 06−
SKAT MED1 17 3 147 8.7 × 10−02 3.4 × 10−01 109.3 × 07− 2.8 × 10−04 1.9 × 10−04 103.9 × 06−
HAL 12 6 42 3.8 × 10−05 5.5 × 10−01 3.5 × 10−03 102.9 × 06− 1.5 × 10−04 1.1 × 10−05
STK33 11 6 180 4.0 × 10−01 2.3 × 10−01 108.9 × 06− 1.1 × 10−03 5.7 × 10−03 3.2 × 10−05
ALDH1L1 3 8 103 4.4 × 10−02 1.1 × 10−01 2.2 × 10−02 1.6 × 10−04 4.2 × 10−04 3.8 × 10−04
BCAT2 19 3 133 9.7 × 10−04 5.0 × 10−01 8.1 × 10−02 2.4 × 10−03 3.5 × 10−03 9.3 × 10−03
GLDC 9 4 183 101.4 × 59− 7.5 × 10−04 101.5 × 15− 101.3 × 64− 102.1 × 54− 9.7 × 10−64
HAL 12 6 42 102.4 × 08− 2.8 × 10−05 4.6 × 10−01 104.2 × 12− 7.9 × 10−03 104.2 × 11−
PAH 12 6 27 4.3 × 10−05 2.0 × 10−01 5.3 × 10−04 107.2 × 06− 9.3 × 10−03 101.3 × 06−
Burden DHODH 16 5 90 101.3 × 07− 5.3 × 10−02 1.3 × 10−02 102.9 × 06− 7.6 × 10−04 107.7 × 06−
BCAT2 19 3 133 108.4 × 06− 4.0 × 10−01 1.7 × 10−02 1.1 × 10−05 6.1 × 10−03 3.7 × 10−05
ALDH1L1 3 8 103 108.3 × 08− 1.7 × 10−02 5.1 × 10−03 102.1 × 06− 1.7 × 10−05 4.2 × 10−05
MED1 17 3 147 9.4 × 10−01 1.8 × 10−01 8.7 × 10−05 2.1 × 10−03 7.1 × 10−01 3.4 × 10−04
STK33 11 6 180 4.8 × 10−01 7.1 × 10−01 7.0 × 10−04 3.8 × 10−02 6.4 × 10−01 6.3 × 10−03
Note. Het: heterogeneous; Hom: homogeneous; MAF: minor allele frequency; minP: minimum P value; PC: principal component; PhC: phenotype covariance;
SNP: single‐nucleotide polymorphism; MAC: minor allele count.
Multi‐SKAT tests were applied with the kinship adjustment, and 5,207 genes with at least three rare (MAF< 0.01) nonsynonymous and protein‐truncating
variants were used in this analysis. The total sample size was n= 8,545. P values smaller than the Bonferroni corrected significance α = 9.6 × 10−6 were marked
as bold. For the upper part of the table, minPhen was calculated as the Bonferroni‐adjusted minimum SKAT P value across each phenotype, whereas for the
lower part, it was calculated as the Bonferroni‐adjusted minimum Burden P value across each phenotype.
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Among other genes, GLDC has the smallest P value.
Variants in GLDC are known to cause glycine encephalo-
pathy (MIM: 605899; Hughes, 2009). To investigate
whether our results were supported by single‐phenotype
associations, we applied SKAT‐O to each of the nine
amino acid phenotypes. Univariate SKAT‐O test with
each of these phenotype reveals that this gene has a
strong association with glycine (P value = 2.5 × 10−64;
Table 5). Among the variants genotyped in this gene,
rs138640017 (MAF= 0.009) appears to drive the associa-
tion (single‐variant P value =1.0 × 10−64). Variants in
HAL cause histidinemia (MIM: 235800) in human and
mouse. This gene shows significant univariate association
with histidine (SKAT‐O P value =3.2 × 10−8; Table 5),
which in turn is influenced by the association of
rs141635447 (MAF= 0.005) with histidine (single‐variant
P value =3.7 × 10−13). Similarly, variants in DHODH,
which have been previously found to be associated with
postaxial acrofacial dysostosis (MIM: 263750), have
significant cross‐phenotype association although the
result is mostly driven by the association with alanine
(SKAT‐O P value =1.4 × 10−07; Table 5). ALDH1L1
catalyzes conversion of 10‐formyltetrahydrofolate to
tetrahydrofolate. Published results show that common
variant rs1107366, 5 kb upstream of ALDH1L1, is
associated with the glycine–creatinine ratio (Xie et al.,
2013. Downregulation of BCAT2 in mice causes elevated
serum branched chain amino acid levels and features of
maple syrup urine disease. Table 3 shows P values of
Multi‐SKAT kernel and minP with two genotype kernels
TABLE 4 P values for genes reported in Table 2 using MSKAT, GAMuT, and Multi‐SKAT (PhC and minPcom)
Unrelated individuals (n= 7,213) All individuals (n= 8,545)
MSKAT MSKAT GAMuT GAMuT PhC PhC
Gene (Q) (Q′) (Projection) (Linear) (ΣG = SKAT) minPcom (ΣG = SKAT) minPcom
GLDC 108.9 × 54− 106.1 × 15− 0* 106.2 × 15− 108.1 × 54− 101.3× 53− 102.9 × 73− 102.3 × 72−
HAL 9.5 × 10−05 4.2 × 10−02 9.6 × 10−05 4.3 × 10−02 9.5 × 10−05 102.9 × 07− 102.9 × 06− 109.5 × 11−
DHODH 102.1 × 06− 2.2 × 10−03 102.4 × 06− 2.2 × 10−03 101.9 × 06− 108.3 × 06− 103.1 × 08− 101.1 × 07−
PAH 9.9 × 10−06 1.3 × 10−02 1.0 × 10−05 1.3 × 10−02 9.9 × 10−06 5.1 × 10−05 103.9 × 07− 101.9 × 06−
MED1 1.7 × 10−03 2.7 × 10−01 1.7 × 10−03 2.7 × 10−01 1.7 × 10−03 2.8 × 10−05 2.8 × 10−04 104.9 × 06−
STK33 6.8 × 10−04 6.9 × 10−01 6.7 × 10−04 6.9 × 10−01 6.7 × 10−04 101.9 × 06− 1.1 × 10−03 4.2 × 10−05
ALDH1L1 5.9 × 10−05 3.1 × 10−02 6.1 × 10−05 3.0 × 10−02 6.0 × 10−05 109.5 × 06− 1.6 × 10−04 5.4 × 10−05
BCAT2 6.1 × 10−04 1.5 × 10−02 6.3 × 10−04 1.5 × 10−02 6.2 × 10−04 3.7 × 10−05 2.4 × 10−03 6.2 × 10−05
Note. minP: minimum P value; PhC: phenotype covariance.
P values in columns 2–7 were calculated with unrelated individuals (n= 7,213), whereas those in columns 8 and 9 were calculated using all individuals
(n= 8,545). Both MSKAT (Q andQ′ statistic) and GAMuT (projection and linear phenotype kernel) P values were calculated with the linear weighted genotype
kernel. DKAT P values were nearly identical to those of GAMuT when the same kernels were used (data not shown). P values smaller than the Bonferroni
corrected significance α = 9.6 × 10−6 were marked as bold.
*GAMuT software collapses any P value lower than 10−50 to 0.
TABLE 5 Single‐phenotype SKAT‐O with kinship adjustment test for the METSIM study data (n= 8,545)
Gene Ala Gln Gly His Ile Leu Phe Tyr Val
GLDC 2.9 × 10−01 2.9 × 10−03 102.5 × 64− 1.0 × 10−02 1.5 × 10−01 3.4 × 10−02 8.5 × 10−01 6.6 × 10−01 4.7 × 10−03
HAL 9.9 × 10−01 1.1 × 10−01 3.1 × 10−01 103.2 × 09− 2.6 × 10−01 2.5 × 10−01 6.6 × 10−01 1.2 × 10−01 3.5 × 10−01
DHODH 101.4 × 07− 9.9 × 10−01 9.0 × 10−02 3.6 × 10−01 7.7 × 10−01 1.7 × 10−01 1.9 × 10−01 3.0 × 10−01 1.0 × 10−02
PAH 7.9 × 10−01 3.0 × 10−01 2.8 × 10−01 8.6 × 10−01 4.5 × 10−01 8.1 × 10−01 6.8 × 10−05 4.0 × 10−01 9.9 × 10−01
MED1 1.0 × 10−01 5.1 × 10−01 7.9 × 10−01 5.9 × 10−01 3.3 × 10−01 1.4 × 10−01 6.9 × 10−01 6.8 × 10−02 6.7 × 10−01
STK33 8.4 × 10−01 8.2 × 10−01 3.5 × 10−01 5.7 × 10−01 6.6 × 10−01 1.0 × 10−01 9.9 × 10−01 8.1 × 10−01 4.1 × 10−01
ALDH1L1 6.7 × 10−01 7.6 × 10−01 109.3 × 09− 7.3 × 10−01 3.4 × 10−01 3.2 × 10−01 9.9 × 10−01 5.9 × 10−01 2.5 × 10−01
BCAT2 1.4 × 10−01 2.6 × 10−01 8.2 × 10−01 9.9 × 10−01 1.0 × 10−01 2.1 × 10−02 5.4 × 10−01 5.0 × 10−01 101.2 × 06−
Note. Ala: alanine; Gln: glutamine; Gly: glycine; His: histidine; Ile: isoleucine; Leu: leucine; METSIM: METabolic Syndrome In Men; Phe: phenylalanine; Tyr:
tyrosine; Val: valine.
P values smaller than the Bonferroni corrected significance α = 9.6 × 10−6 were marked as bold.
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(SKAT and Burden). Among phenotype kernels, PhC and
Het generally produced the smallest P values. We further
applied Multi‐SKAT tests without kinship adjustment on
the whole METSIM study individuals. As expected, this
produced inflation in QQ plots (Supporting Information
Figure S5).
To directly compare our results with existing methods,
we applied GAMuT, DKAT, and MSKAT to the METSIM
data set. Because these methods cannot be applied to
related individuals, we eliminated 1,332 individuals that
were related up to second degree, leaving us 7,213
individuals. Table 4 shows P values of different methods
on the eight significant or suggestive genes displayed in
Table 2. Because DKAT and GAMuT had nearly identical
P values when the same kernels were used, DKAT P
values were not shown in Table 4. For unrelated
individuals, as expected, P values produced by MSKAT
with Q statistic, GAMuT with projection phenotype
kernel and PhC (with SKAT ΣG) were very similar, and
minPcom provided similar or more significant P values
than PhC. Interestingly, MSKAT with Q′ statistic and
GAMuT with linear phenotype kernel have less signifi-
cant P values than the other tests. We found that in five of
the eight genes in Table 4, using all individuals with
kinship correction produced more significant PhC and
minPcom P values than using only unrelated individuals.
Further, we have listed the top 10 genes for each of PhC,
GAMuT, and MSKAT with unrelated individuals (Sup-
porting Information Table S4). Except for the genes in
Table 4, no other genes were found to be significant or
suggestive.
Overall, our METSIM amino acid data analysis
suggests that the proposed method can be more
powerful than the single‐phenotype tests as well as
existing tests, while maintaining Type I error rate even
in the presence of the relatedness. It also shows that
the omnibus tests (minP and minPcom) provide robust
performance by effectively aggregating results of
various kernels.
4.4 | Computation time
When ΣP and ΣG are given, P values of Multi‐SKAT are
computed by the Davies (1980) method, which inverts the
characteristic function of the mixture of Χ2. On average,
Multi‐SKAT tests for a given ΣP and ΣG required less than
1 CPU‐sec (Intel Xeon 2.80 GHz, Produced by Intel Co.,
Santa Clara, CA) when applied to a data set with 5,000
independent individuals, 20 variants, and 10 phenotypes
(Supporting Information Table S1). With the kinship
adjustment for 5,000 related individuals, computation
time was increased to 3 CPU‐sec. Because minPcom
requires only a small number of resampling steps to
estimate the correlation among tests, it is still scalable for
genome‐wide analysis. In the same data set, minPcom
required 4 and 10 CPU‐sec on average without and with
the kinship adjustment, respectively. Further, Multi‐
SKAT, given ΣP and ΣG, is computationally equivalent
to MSKAT and takes less than 1 CPU‐sec for up to 20,000
samples, with 20 variants (Supporting Information Figure
S7a), whereas GAMuT takes considerably more time than
these two. The performance of minPcom is similar to
GAMuT for small and moderate sample sizes (7.5 and
7.1 CPU‐sec, respectively, for 10,000 samples) and per-
forms better than GAMuT for larger sample sizes (14.9
and 34.6 CPU‐sec, respectively, for 20,000 samples).
Computation times of all the methods were slightly
increased when the number of variants was 100
(Supporting Information Figure S7b). Analyzing the
METSIM data set with minPcom required 10 hr when
parallelized into five processes.
5 | DISCUSSION
In this study, we have introduced a general framework for
rare‐variant tests for multiple phenotypes. As demonstrated,
Multi‐SKAT gains flexibility with regard to modeling the
relationship between phenotypes and genotypes through
the use of the kernels ΣP and ΣG. Many published methods,
including GAMuT, MSKAT, and MAAUSS, can be viewed
as special cases of the Multi‐SKAT test with corresponding
values of ΣP and ΣG, which illuminates the underlying
assumptions of these methods and their relationships. In
addition, by unifying existing methods to the common
framework, our approach provides a way to combine
different methods through the minimum P value‐based
omnibus test. Our method can also adjust for sample
relatedness. From simulation studies, we have found that
the proposed method is scalable to genome‐wide analysis
and can outperform the single‐phenotype test and existing
multiple‐phenotype tests. The METSIM data analysis
demonstrated that the proposed methods perform well in
practice.
It is natural to assume that different genes follow
different models of association. For some genes, the effect
of the variants on the phenotypes might be independent
of each other, thus best detected by the Het phenotype
kernel for ΣP, whereas for others, the effects might be
nearly the same and best detected by the Hom phenotype
kernel. If the kernel structures are chosen based on prior
knowledge and the selected ΣG and ΣP do not reflect
underlying biology, the test may have substantially
reduced power. The omnibus test, which uses the
minimum P value from the various choices of kernels,
has been a useful approach under such situations in
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genetic association analysis (Lee, Wu et al., 2012; Urrutia
et al., 2015; Zhan et al., 2017). We applied this omnibus
test to Multi‐SKAT and used a Copula to obtain P values.
As seen in simulation studies and real data analysis, our
omnibus approaches (minP and minPcom) are scalable to
genome‐wide analysis and provide robust power regard-
less of underlying genetic models.
Multi‐SKAT retains most of the desirable properties of
SKAT. The asymptotic P values of all the Multi‐SKAT
tests, other than minP and minPcom, can be analytically
obtained via Davies’ method. The P value calculations for
minP and minPcom depend on a resampling‐based
approach but a reliable estimate can be obtained using
a small number of resampling steps. Thus, computation-
ally, all the Multi‐SKAT tests are scalable at the genome‐
wide level. This method also allows the inclusion of prior
information through weighting of variants.
Additionally, Multi‐SKAT can adjust for the related-
ness among study individuals by accounting for their
kinship matrix. As shown in Supporting Information
Figure S5, in the presence of related individuals, lack of
adjustment for relatedness can produce inflated Type I
error rate. Because Multi‐SKAT is a regression‐based
approach, it effectively incorporates the relatedness by
including a random effect term for kinship. Type I error
simulation and METSIM data analysis show that our
approach produced more significant P values than
alternative methods, like GAMuT and MSKAT, while
controlling Type I error rates.
Although Multi‐SKAT provides a general framework
for gene‐based multiple‐phenotype tests, the current
approach is limited to continuous phenotypes. In the
future, using a generalized mixed effect model
framework, we aim to extend Multi‐SKAT to binary
phenotypes.
In summary, we have developed a powerful multiple‐
phenotype test for rare variants. The proposed method
has robust power regardless of the underlying biology
and can adjust for family relatedness. Our method can be
a scalable and practical solution to test for multiple
phenotypes and will contribute to detecting rare variants
with pleiotropic effects. All our methods are implemen-
ted in the R‐package Multi‐SKAT (see Web Resource).
6 | WEB RESOURCES
Multi‐SKAT R‐package: https://github.com/diptavo/
MultiSKAT.
GAMuT R‐package: https://epstein‐software.github.io/
GAMuT.
MSKAT R‐package: https://github.com/baolinwu/MSKAT.
PHENIX R‐package: https://mathgen.stats.ox.ac.uk/
genetics/_software/phenix/phenix.html.
KING: http://people.virginia.edu/~wc9c/KING/
Online Mendelian Inheritance in Man (OMIM): http://
www.omim.org.
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APPENDIX A: PRINCIPAL COMPONENT
(PC) KERNEL
Let Li be the loading vector for the ith PC, which
produces the ith PC score P YL=i i. In PCA‐based
analysis, PC scores are used as outcomes instead of
original Y . Because the genetic information regarding the
phenotypes may not be confined to the top few PCs
(Aschard et al., 2014), we first consider using all PCs. Let
P P P= ( , …, )K1 . Because PCs are orthogonal, we assume
genetic effects to multiple PCs are heterogeneous, which
resulted in


 ⊗Q P μ G G V V P
μ
= {vec( ) − vec( )} {( Σ ) ( )}{vec( )
− vec( )},
P
T
G
T
P P
P
−1 −1
(A1)
where μP is the mean of P under the null hypothesis andVP the estimated covariance matrix between the PCs. VP
will be a diagonal matrix because PCs are orthogonal.
Equation (A1) can be written as
 ⊗
Q Y μ G G
LV V L Y μ
= {vec( ) − vec( ˆ)} {( Σ )
( )}{vec( ) − vec( ˆ)},
T
G
T
P P
T−1 −1 (A2)
where L L L= ( , …, )K1 is a K K× PC loading matrix.
Equation (A2) shows that by using Σ =P,PC
   VLV V L VP P T−1 −1 , we can carry out PC‐based tests. It is to
be noted that the genetic effects of the PCs do not need to
be assumed to be heterogeneous. Any kernel structure
that is applicable to the test statistic in Equation (4) can
be applied here as well.
APPENDIX B: RELATIONSHIP BETWEEN
MULTI ‐SKAT AND EXISTING METHODS
For the ease of algebraic expressions, we will consider
that all the K phenotypes have residual variance 1. For
the general case of different residual variances, ΣP
should be replaced by T TΣw P w−1 −1, where
T σ σ= diag( , …, )w K1 , σk being the residual standard error
of kth phenotype.
B.1 | MSKAT
The Q statistic of MSKAT (Wu & Pankow, 2016) is
given by
⊗Q S WW V S= vec( ) ( )vec( ),TMSKAT c −1 c (B1)
where S G Y μ= ( − )Tc is a matrix of score statistics (Wu
& Pankow, 2016). Using row‐vectorization properties,
 

⊗
⊗
S G Y μ G I Y μ
G I Y μ
vec( ) = vec( ( − )) = ( )vec( − )
= ( ){vec( ) − vec( )}.
T T
T
c
Then QMSKAT can be written as


⊗Y μ V Y
μ
{vec( ) − vec( )} {(GWWG ) }{vec( )
− vec( )},
T T −1
which is the Multi‐SKAT test statistics with WWΣ =G
and VΣ =P .
Further, the Q′ of MSKAT is given by
⊗Q S WW I S= vec( ) ( )vec( ).TMSKAT′ c c (B2)
Using the similar algebra as above, this can be written as
 ⊗Y μ I Y μ{vec( ) − vec( )} {(GWWG ) }{vec( ) − vec( )},T T
which is the Multi‐SKAT test statistics with WWΣ =G
and VΣ =P 2.
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B.2 | GAMuT
Suppose Y μ Y HY− = =adj andG HG=adj are covariate‐
adjusted phenotype and genotype matrices, where
H I X X X X= − ( )T T−1 . With the intercept in X , Yadj and
Gadj are mean centered. The covariate‐adjusted GAMuT
test statistics is
Q P X
n
= tr( ) ,GAMuT c c
where
⎧
⎨
⎪⎪
⎩
⎪⎪
P
Y Y Y Y
Y Y
=
( ) for projection phenotype 
kernel,
for linear phenotype kernel
T T
T
c
adj adj adj
−1
adj
adj adj
and X G WWG= Tc adj adj. Using the fact that ∕Y Y n V=Tadj adj
is the estimate of variance after adjusting covariates
and G Y G HY G= = YT T Tadj adj adj (because H is a sym-
metric idempotent matrix), we show, for the projection
kernel,



 
 
 

∕
⊗ ⊗
⊗
P X n Y V Y G WWG
V Y GWWG Y V
WG Y V WG Y V
WG V Y WG V
Y
Y μ GWWG V
Y μ
tr( ) = tr( )
= tr( )
= vec( ) vec( )
= {( )vec( )} {( )
vec( )}
= {vec( ) − vec( )} ( )
{vec( ) − vec( )},
T T
T T
T T T
T T T
T T
c c adj
−1
adj adj adj
−
adj adj
−
adj
−
adj
−
−
adj
−
adj
−1
1
2
1
2
1
2
1
2
1
2
1
2
which is the same as the Multi‐SKAT test statistic with
WWΣ =G and VΣ =P . Similarly for the linear kernel,


∕
⊗ ⊗
⊗
P X n Y Y G WWG
WG I Y WG I
Y
Y μ GWWG I
Y μ
tr( ) = tr( )
= {( )vec( )} {( )
vec( )}
= {vec( ) − vec( )} ( )
{vec( ) − vec( )},
T T
T T T
T T
c c adj adj adj adj
adj
adj
which is the Multi‐SKAT test statistic with WWΣ =G
and VΣ =P 2.
B.3 | MAAUSS and MF‐KM
There exist two different versions of the MAAUSS tests.
The homogeneous version of MAAUSS assumes that the
effects of a variant on multiple phenotypes are identical
and use the following test statistic:




⊗
⊗ ⊗ ⊗
⊗
Q Y μ I V
G I WW G I
I V Y μ
= (vec( ) − vec( )) ( )
( )( 1 1 )( )
( )(vec( ) − vec( )),
T
n
m m
T T
n
MAAUSS‐HOM
−1
−1 (B3)
which is identical to the Multi‐SKAT test statistic with
WWΣ =G and Σ = 1 1P m mT . The heterogeneous version of
MAAUSS assumes that the effects of a variant on
multiple phenotypes are independent and use the
following test statistic:




⊗
⊗ ⊗ ⊗
⊗
Q Y μ I V
G I WW I G I
I V Y μ
= (vec( ) − vec( )) ( )
( )( )( )
( )(vec( ) − vec( )),
T
n
T
n
MAAUSS‐HET
−1
−1 (B4)
which is identical to the Multi‐SKAT test statistic with
WWΣ =G and IΣ =P . Note that the test statistic of
MF‐KM is exactly the same as QMAAUSS‐HET.
APPENDIX C: BACKWARD ELIMINATION
PROCEDURE TO IDENTIFY ASSOCIATED
PHENOTYPES
After identifying the gene or region associated with
multiple phenotypes, next question would be identify-
ing truly associated phenotypes. Here, we present a
simple backward elimination algorithm to iteratively
remove relatively less important phenotypes. A similar
method has previously been applied to identify rare
causal variants in an associated gene (Ionita‐Laza
et al., 2014.
• Step 1. Start with a set of k phenotypes
y y yPhen = { , , …, }kCurrent 1 2 and compute a Multi‐SKAT
test association P value for the set PhenCurrent denoted
by pCurrent.
• Step 2. Remove each of the phenotypes one at a time
from the set PhenCurrent. The resulting set is
y y y y yPhen = { , , …, , , …, }i i i k− 1 2 −1 +1 for i k= 1, 2, …,
and computes the corresponding P values p i− for that
the same Multi‐SKAT test.
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• Step 3. Remove the phenotype j that leads to the
smallest P value, that is, j p p p= argmin{ , , …, }k−1 −2 − .
Update PhenCurrent to Phen j− .
• Step 4. Continue removing phenotypes till only one
phenotype is left.
Supporting Information Table S2 shows the back-
ward elimination results of five most significant and
suggestive genes in the METSIM study data analysis as
per the P values reported by minPcom. Although this
procedure does not provide a set of phenotypes truly
associated, it provides the relative importance of the
phenotypes in driving association signals. For example,
the minPcom P value for GLDC was 2.3 × 10−72. When
each of the phenotypes was removed one at a time and
the minPcom P values were calculated on the remaining
eight phenotypes, we found that eliminating isoleucine
(Ile) actually improved the signal. The minPcom P value
of the set of eight amino acids leaving out Ile was
2.8 × 10−73. This indicates that isoleucine has very
minimal contribution to the association between the
amino acids and GLDC. Subsequently, valine was the
next phenotype to be eliminated indicating that it has
the next lowest contribution after isoleucine. Carrying
out this procedure further, we find that glycine is the
last phenotype to remain indicating that it is the
strongest driver of the signal. This is in agreement to
the single‐phenotype SKAT‐O results (Table 5). Simi-
larly for genes HAL, DHODH, PAH, and MED1,
histidine, alanine, phenylalanine, and tyrosine were
the most associated phenotypes, respectively. Interest-
ingly for PAH and MED1, single‐phenotype P values
are not significant, which suggests that multiple
phenotypes are associated with these genes.
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